Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind comparison of EP2006 vs Neupogen in TAC-treated breast cancer
2010-024481-22Phase 3Completed
- Sponsor
- Sandoz
- Start
- Oct 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of filgrastim in breast cancer (2 arms), sponsored by Sandoz. Primary endpoint: Mean duration of severe neutropenia in Cycle 1. Started Oct 2011; status: completed.
02
Drugs
filgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-024481-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024481-22.